Advertisement
New Zealand researchers are launching a long-Covid registry to get an accurate picture of the country’s post-pandemic burden.
The passing of the Therapeutic Products Bill marks the most significant change to the regulation of medicines, medical devices and natural health products in New Zealand in nearly 40 years, said health minister Dr Ayesha Verrall.
The New Zealand Association of Optometrists (NZAO) is hosting its very first peer-support conference for hospital optometrists on 2 September at the Rydges Wellington Airport hotel.
In the six years since publication of the evidence-based TFOS DEWS II reports¹, awareness and acknowledgement of dry eye disease (DED) as a growing global concern has continued to intensify. These reports reached consensus with respect to the diagnosis, classification, diagnosis and management of DE
In a world first, ophthalmologists at Flinders University, South Australia, will trial an early-intervention laser treatment designed to treat people at high risk of losing sight from glaucoma.
The Ocular Surface Laboratory’s team of clinician scientists at the University of Auckland is dedicated to improving patient outcomes through developing a better understanding of ocular surface and
A genetic saliva test indicating glaucoma risk is expected to be available to eyecare professionals by the end of this year, with its Australian developers saying it could also warn of aggressive
Ocuphire Pharma announced its Zeta-1 phase 2 trial showed oral diabetic retinopathy (DR) treatment APX3330 reduced patients’ progression on the diabetic retinopathy severity scale (DRSS) after 24
Bespoke protective ‘sunglasses’ designed for puffins helped researchers demonstrate the birds’ bills fluoresce in ultraviolet (UV) light.
The World Health Organization (WHO) reported the number of people at risk from trachoma, the world's leading infectious cause of blindness, fell from 125 million in 2022 to 115.7m in 2023. In 2022,
Glaukos announced it has entered into a collaboration and marketing agreement with Radius XR, the developers of a diagnostic device to conduct patient-guided vision exams. A Glaukos statement